Norwegian University of Science and Technology
Trondheim, 7491, Norway
NCT Number: NCT01325675
The purpose of this study is to determine the effect of aerobic interval training in patients with paroxysmal or persistent atrial fibrillation, especially to see if the burden of atrial fibrillation and symptoms are reduced.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Trondheim, 7491, Norway
Long term endurance sport practice is associated with a higher incidence of atrial fibrillation. Moderate/light physical activity seems to be associated with a lower incidence. The underlying mechanisms are uncertain. In order to examine the effect of training in this population, the investigators will perform a randomised controlled study with aerobic interval training in patients with paroxysmal/persistent atrial fibrillation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
Time frame: Baseline and 4 weeks after ended intervention period
Burden of atrial fibrillation(number of episodes, duration(percent of the day)) continually measured, and reported by the patient. Analysed for the patients in total, with sub analysis in the groups of paroxysmal and persistent AF and in those with a low burden of atrial fibrillation vs. those with a larger burden.
Time frame: Baseline and after ended intervention period(12 weeks)
Atrial and ventricular size will be evaluated by echocardiography and MRI.
Time frame: Baseline and after ended intervention period(12 weeks)
Interleukin-6, pro-BNP, d-dimer and von Willenbrands factor are measured.
Time frame: Baseline and after ended intervention period(12 weeks)
FMD
Time frame: Baseline and after ended intervention period(12 weeks)
Atrial extrasystoles on 48h Holter monitoring. Will alse be measured in the first week of training.
Time frame: Measured during the ablation procedure (day 1)
Duration of ablation, number of ablation points, success.
Time frame: Baseline and after ended intervention period(12 weeks)
Time frame: Baseline and after ended intervention period(12 weeks)
Atrial and ventricular function measured by MR and echocardiography
Time frame: Baseline and after ended intervention period(12 weeks)
Fibrosis in left atrium and left ventricle measured by MRI.
Time frame: Baseline and after ended intervention period(12 weeks)
Measured with SF-36, Symptom and Severity Checklist and EHRA score of AF- related symptoms
Time frame: Week 1-4, 5-8 and 9-12
The intervention period is divided into 3 periods of 4 weeks each. The mean burden of atrial fibrillation(percent of time with atrial fibrillation) and number of episodes in each of those periods will be assessed to see if exercise changes the amount of fibrillation.
Norwegian University of Science and Technology
Other
Aerobic Interval Training in Patients With Paroxysmal or Persistent Atrial Fibrillation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05085860
Arrhythmias, Cardiac, Atrial Fibrillation
Ottawa, Ontario, Canada
View Trial DetailsNCT06575348
Arrhythmias, Cardiac, Atrial Fibrillation
Madison, Wisconsin, United States
View Trial DetailsNCT03241433
Arrhythmias, Cardiac, Atrial Fibrillation
Minneapolis, Minnesota, United States
View Trial DetailsNCT02493400
Arrhythmias, Cardiac, Atrial Fibrillation
Gothenburg, Sweden
View Trial Details